Core Viewpoint - Chengdu High-tech Zone is actively promoting technological innovation and industrial integration to enhance new productive forces and economic growth, aiming to establish itself as a world-leading technology park [2][3][4]. Group 1: Technological Innovation and Industrial Integration - Chengdu High-tech Zone has established 8 strategic platforms and 70 national-level innovation platforms, leading the province in high-value invention patents per capita [3]. - The zone has developed key technologies such as the world's first gallium nitride quantum light source chip and mRNA therapies for hepatitis B, showcasing significant breakthroughs in core technology [3][4]. - A "mid-test +" ecosystem has been created with 102 mid-test platforms, attracting nearly 10 billion yuan in investment and generating over 18 billion yuan in product output [4]. Group 2: Business Environment and Economic Growth - The Chengdu High-tech Comprehensive Bonded Zone achieved an import and export value of 525.69 billion yuan in 2025, marking a 4.8% year-on-year increase, maintaining its position as the top bonded zone in the country [6]. - The zone has implemented innovative regulatory measures, reducing customs clearance times from 5 days to under 1 day, significantly lowering logistics costs by 30% [6]. - The total number of business entities in Chengdu High-tech Zone surpassed 400,000, with 274,100 being enterprises, the highest in the city [8]. Group 3: Consumer and Cultural Development - Chengdu High-tech Zone has launched various cultural and tourism initiatives, attracting over 120,000 participants to events like the "Chengdu Lights You Up" New Year celebration [9]. - The zone is home to over 6,000 digital cultural and creative enterprises, enhancing consumer experiences and driving new consumption patterns [10]. - The area has seen a significant increase in talent, with over 850,000 individuals contributing to innovation and consumption potential, thereby enhancing regional attractiveness [10][11].

PrimRNA属于NANO MRNA的子公司。PrimRNA的澳大利亚法人将启动临床试验。本次试验 基于大阪大学的位高启史教授等研究团队的成果。位高教授将作为顾问参与临床试验。NANO MRNA透露，这是日本国内企业首次进行基于mRNA的治疗药物的临床试验。 mRNA是一种从DNA复制遗传信息，按照设计图制造蛋白质的物质。只要了解与疾病预防或 治疗相关的蛋白质序列，就能通过投入mRNA 来设计（药物）。与传统技术相比，可以更快 地开发药物。 本次试验基于大阪大学的位高启史教授的研究成果（图片由位高启史教授提供） 针对膝盖软骨磨损、没有根本性疗法的膝关节退行性关节病（膝关节骨关节炎），日企将启 动注射mRNA进行治疗的临床试验。mRNA作为疫苗已首次被应用于医疗，但从未用于治疗药 物…… 日本生物企业PrimRNA（位于东京都港区）最早9月在澳大利亚针对膝盖软骨磨损、没有根本 性疗法的膝关节退行性关节病（膝关节骨关节炎），启动治疗药物的临床试验。向患者注 射"信使RNA（mRNA）"，提高制造胶原蛋白等的软骨细胞的功能。mRNA作为疫苗已首次 被应用于医疗，但从未用于治疗药物。如果能实现实用化，新药研发方法的选 ...